Atevirdine mesylate: Clinical Trials

4 completed. 2 Phase 1, 1 Not applicable, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	2	Completed 2
Not applicable	1	Completed 1
Phase 2	1	Completed 1

Follow Atevirdine mesylate: new trials by email Literature Review of Atevirdine mesylate trials Research Report on Atevirdine mesylate

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC Atevirdine mesylate, Zidovudine, Zalcitabine - HIV Infections	Phase 1	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	30		2021-11-04
A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients Atevirdine mesylate, Zidovudine - HIV Infections	Phase 2	Completed	Pharmacia and Upjohn			2005-06-24
Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E Atevirdine mesylate - HIV Infections	Not applicable	Completed	Pharmacia and Upjohn			2005-06-24
A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI) Atevirdine mesylate, Zidovudine, Didanosine - HIV Infections	Phase 1	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	15		2021-11-04

Conditions studied

Acquired Immunodeficiency Syndrome (4)  ·  HIV Infections (4)  ·  AIDS-Related Complex (3)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  Pharmacia and Upjohn (2)

Countries

United States (4)

Top investigators

Reichman R (2)